Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Inclusion criteria

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
• Healthy and non-healthy male or female aged 41 years or older at the time of the first vaccination.
• Written informed consent obtained from the subject.
• No serological signs of hepatitis A or B infection at screening.
• If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.

Exclusion criteria

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• History of any hepatitis A or hepatitis B vaccination or infection, since the primary vaccination study 100382.
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Acute disease at the time of enrolment. .
• Pregnant or lactating female.
• Female planning to become pregnant or planning to discontinue contraceptive precautions during the primary vaccination period.